Terms: = Prostate cancer AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Diagnosis
6 results:
1. Predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2013 May; 23(3):245-51. PubMed ID: 23478499
[TBL] [Abstract] [Full Text] [Related]
2. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.
Prapotnich D; Cathelineau X; Rozet F; Barret E; Mombet A; Cathala N; Sanchez-Salas RE; Vallancien G
World J Urol; 2009 Oct; 27(5):627-35. PubMed ID: 19247669
[TBL] [Abstract] [Full Text] [Related]
3. Real-time quantitative RT-PCR assessment of pim-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.
He HC; Bi XC; Zheng ZW; Dai QS; Han ZD; Liang YX; Ye YK; Zeng GH; Zhu G; Zhong WD
Med Oncol; 2009; 26(3):303-8. PubMed ID: 19003546
[TBL] [Abstract] [Full Text] [Related]
4. Detection of pim-1 mRNA in prostate cancer diagnosis.
He HC; Bi XC; Dai QS; Wang SS; Wei HA; Zhong WD; Liu WH; Jiang FN; Liu LS
Chin Med J (Engl); 2007 Sep; 120(17):1491-3. PubMed ID: 17908456
[TBL] [Abstract] [Full Text] [Related]
5. prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.
Bindukumar B; Schwartz SA; Nair MP; Aalinkeel R; Kawinski E; Chadha KC
Neoplasia; 2005 Mar; 7(3):241-52. PubMed ID: 15799824
[TBL] [Abstract] [Full Text] [Related]
6. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.
Rhodes DR; Sanda MG; Otte AP; Chinnaiyan AM; Rubin MA
J Natl Cancer Inst; 2003 May; 95(9):661-8. PubMed ID: 12734317
[TBL] [Abstract] [Full Text] [Related]
